ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC

ESMO 2022: Highlights, commentary and analysis

ESMO 2022: Renal roundup

Fruquintinib provides improvement in overall survival for refractory mCRC

Emerging systemic therapies in rare urothelial cancer variants

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

A new era of early cancer detection with blood test may change cancer screening paradigms

Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for squamous NSCLC